GlassScriptPhysician profile
Theodore E Loizos
NPI 1497836290
$5,170.76
in general payments reported to CMS, 2019-2025
25 companies · $966 in 2025
The $966 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $447 · 2021: $383 · 2022: $500 · 2023: $1,080 · 2024: $1,081 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,763.75 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Biotissue Holdings INC. | $324.61 | 2019-2025 | |
| Ivantis, INC | $308.38 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $308.35 | 2019-2021 | |
| Allergan, INC. | $261.75 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $256.78 | 2019-2023 | Cequa |
| Ocular Therapeutix, INC. | $208.82 | 2020-2025 | Dextenza |
| Abbvie INC. | $207.70 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $196.35 | 2022-2025 | Miebo, Vyzulta, Prolensa |
| Tarsus Pharmaceuticals, INC. | $192.45 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $172.50 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Oyster Point Pharma, INC. | $150.32 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $114.58 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $104.35 | 2024-2025 | Idosetr, Istent Infinite, Idose |
| Novartis Pharmaceuticals Corporation | $101.05 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $89.44 | 2022-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $72.27 | 2022-2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Kala Pharmaceuticals, INC. | $67.55 | 2019-2021 | |
| New World Medical,INC. | $63.35 | 2022-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Horizon Therapeutics Plc | $47.20 | 2022-2023 | Tepezza |
| Harrow Eye, LLC | $44.19 | 2024-2025 | Vevye, Iheezo, Triesence |
| Aerie Pharmaceuticals, INC. | $43.49 | 2019 | |
| Shire North American Group INC | $29.67 | 2019 | |
| Rxsight INC | $27.52 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Amgen INC. | $14.34 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Loizos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.